These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 32658606)
1. AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins. Evers MM; Konstantinova P Expert Opin Biol Ther; 2020 Oct; 20(10):1121-1124. PubMed ID: 32658606 [No Abstract] [Full Text] [Related]
2. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. Spronck EA; Brouwers CC; Vallès A; de Haan M; Petry H; van Deventer SJ; Konstantinova P; Evers MM Mol Ther Methods Clin Dev; 2019 Jun; 13():334-343. PubMed ID: 30984798 [TBL] [Abstract][Full Text] [Related]
3. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561 [TBL] [Abstract][Full Text] [Related]
4. Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models. Sogorb-Gonzalez M; Landles C; Caron NS; Stam A; Osborne G; Hayden MR; Howland D; van Deventer S; Bates GP; Vallès A; Evers M Brain; 2024 Dec; 147(12):4043-4055. PubMed ID: 39155061 [TBL] [Abstract][Full Text] [Related]
5. Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology. Spronck EA; Vallès A; Lampen MH; Montenegro-Miranda PS; Keskin S; Heijink L; Evers MM; Petry H; Deventer SJV; Konstantinova P; Haan M Brain Sci; 2021 Jan; 11(2):. PubMed ID: 33498212 [TBL] [Abstract][Full Text] [Related]
6. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes. Keskin S; Brouwers CC; Sogorb-Gonzalez M; Martier R; Depla JA; Vallès A; van Deventer SJ; Konstantinova P; Evers MM Mol Ther Methods Clin Dev; 2019 Dec; 15():275-284. PubMed ID: 31737741 [TBL] [Abstract][Full Text] [Related]
7. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548 [TBL] [Abstract][Full Text] [Related]
8. Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study. Morais RDVS; Sogorb-González M; Bar C; Timmer NC; Van der Bent ML; Wartel M; Vallès A Cells; 2022 Sep; 11(17):. PubMed ID: 36078156 [TBL] [Abstract][Full Text] [Related]
9. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease. Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975 [TBL] [Abstract][Full Text] [Related]
10. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. Miniarikova J; Evers MM; Konstantinova P Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201 [TBL] [Abstract][Full Text] [Related]
11. Translating Antisense Technology into a Treatment for Huntington's Disease. Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the therapeutic development for Huntington disease. Mestre TA Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867 [TBL] [Abstract][Full Text] [Related]
13. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients. van Roon-Mom WMC; Roos RAC; de Bot ST Nucleic Acid Ther; 2018 Apr; 28(2):59-62. PubMed ID: 29620999 [TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516 [TBL] [Abstract][Full Text] [Related]
17. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics. Stanek LM; Bu J; Shihabuddin LS Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572 [TBL] [Abstract][Full Text] [Related]
18. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695 [TBL] [Abstract][Full Text] [Related]
19. Aerosol Inhalation-mediated Delivery of an Adeno-associated Virus 5-expressed Antagonistic Interleukin-4 Mutant Ameliorates Experimental Murine Asthma. Tian LC; Zhu QQ; Li J; Liu AJ; Huang GR Arch Med Res; 2019 Aug; 50(6):384-392. PubMed ID: 31678897 [TBL] [Abstract][Full Text] [Related]
20. Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA. Kim KH; Abu Elneel K; Shin JW; Keum JW; Seong D; Kwak S; Lee R; Gusella JF; MacDonald ME; Seong IS; Lee JM J Hum Genet; 2019 Oct; 64(10):995-1004. PubMed ID: 31296921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]